Intracellular metabolism and potential cardiotoxicity of a β-D-2’-C-methyl-2,6-diaminopurine ribonucleoside phosphoramidate that inhibits hepatitis C virus replication

References

• Schinazi, R. F.; Shi, J.; Whitaker, T. Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor. In Innovative Drug Synthesis, 1st ed.; Li, J. J., Johnson, D. S., Eds. John Wiley and Sons, Inc: Hoboken, New Jersey, 2016; pp 61–79.
   Google Scholar
• McCown, M. F.; Rajyaguru, S.; Le Pogam, S.; Ali, S.; Jiang, W. R.; Kang, H.; Symons, J.; Cammack, N.; Najera, I. The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors. Antimicrob. Agents Chemother 2008, 52, 1604–1612. DOI: 10.1128/AAC.01317-07.
   PubMed Web of Science ®Google Scholar
• Xie, Y.; Ogah, C. A.; Jiang, X.; Li, J.; Shen, J. Nucleoside Inhibitors of Hepatitis C Virus NS5B Polymerase: A Systematic Review. Curr. Drug Targets 2016, 17, 1560–1576. DOI: 10.2174/1389450117666151209123751.
   PubMed Web of Science ®Google Scholar
• Coats, S. J.; Garnier-Amblard, E. C.; Amblard, F.; Ehteshami, M.; Amiralaei, S.; Zhang, H. W.; Zhou, L. H.; Boucle, S. R.; Lu, X.; Bondada, L.; et al. Chutes and Ladders in Hepatitis C Nucleoside Drug Development. Antiviral Res. 2014, 102, 119–147. DOI: 10.1016/j.antiviral.2013.11.008.
   PubMed Web of Science ®Google Scholar
• McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Brancale, A.; Zonta, N.; Chamberlain, S.; Vernachio, J.; Hutchins, J.; Hall, A.; et al. Design, Synthesis and Evaluation of a Novel Double Pro-Drug: INX-08189. A New Clinical Candidate for Hepatitis C Virus. Bioorg. Med. Chem. Lett. 2010, 20, 4850–4854. DOI: 10.10/j.bmcl.2010.06.094.
   PubMed Web of Science ®Google Scholar
• Neopentyl ((((2R,3R,4R,5R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alaninate.
   Google Scholar
• Ahmad, T.; Yin, P.; Saffitz, J.; Pockros, P. J.; Lalezari, J.; Shiffman, M.; Freilich, B.; Zamparo, J.; Brown, K.; Dimitrova, D.; et al. Cardiac Dysfunction Associated with a Nucleotide Polymerase Inhibitor for Treatment of Hepatitis C. Hepatology 2015, 62, 409–416. DOI: 10.1002/hep.27488.
   PubMed Web of Science ®Google Scholar
• Fleischer, R.; Boxwell, D.; Sherman, K. E. Nucleoside Analogues and Mitochondrial Toxicity. Clin. Infect. Dis. 2004, 38, E79–E80. DOI: 10.1086/383151.
   PubMed Web of Science ®Google Scholar
• Lewis, W.; Day, B. J.; Copeland, W. C. Mitochondrial Toxicity of NRTI Antiviral Drugs: An Integrated Cellular Perspective. Nat. Rev. Drug Discov. 2003, 2, 812–822. DOI: 10.1038/nrd1201.
   PubMed Web of Science ®Google Scholar
• Feng, J. Y.; Xu, Y.; Barauskas, O.; Perry, J. K.; Ahmadyar, S.; Stepan, G.; Yu, H.; Babusis, D.; Park, Y.; McCutcheon, K.; et al. Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus. Antimicrob. Agents Chemother. 2016, 60, 806–817. DOI: 10.1128/AAC.01922-15.
   PubMed Web of Science ®Google Scholar
• Arnold, J. J.; Sharma, S. D.; Feng, J. Y.; Ray, A. S.; Smidansky, E. D.; Kireeva, M. L.; Cho, A.; Perry, J.; Vela, J. E.; Park, Y.; Y.; et al. Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependent Nuclear Transcription to Antiviral Ribonucleosides. PLoS Pathog. 2012, 8, e1003030. DOI: 10.1371/journal.ppat.1003030.
   PubMed Web of Science ®Google Scholar
• Feng, J. Y.; Tay, C. H.; Ray, A. S. Role of Mitochondrial Toxicity in BMS-986094-Induced Toxicity. Toxicol. Sci. 2017, 155, 2. DOI: 10.1093/toxsci/kfw224.
   PubMed Web of Science ®Google Scholar
• Baumgart, B. R.; Wang, F.; Kwagh, J.; Storck, C.; Euler, C.; Fuller, M.; Simic, D.; Sharma, S.; Arnold, J. J.; Cameron, C. E.; et al. Effects of BMS-986094, a Guanosine Nucleotide Analogue, on Mitochondrial DNA Synthesis and Function. Toxicol. Sci. 2016, 153, 396–408. DOI: 10.1093/toxsci/kfw135.
   PubMed Web of Science ®Google Scholar
• Furman, P. A.; Murakami, E.; Niu, C.; Lam, A. M.; Espiritu, C.; Bansal, S.; Bao, H.; Tolstykh, T.; Micolochick Steuer, H.; Keilman, M.; et al. Activity and the Metabolic Activation Pathway of the Potent and Selective Hepatitis C Virus Pronucleotide Inhibitor PSI-353661. Antiviral Res. 2011, 91, 120–132. DOI: 10.1016/j.antiviral.2011.05.003.
   PubMed Web of Science ®Google Scholar
• Jin, Z.; Kinkade, A.; Behera, I.; Chaudhuri, S.; Tucker, K.; Dyatkina, N.; Rajwanshi, V. K.; Wang, G.; Jekle, A.; Smith, D. B.; et al. Structure-Activity Relationship Analysis of Mitochondrial Toxicity Caused by Antiviral Ribonucleoside Analogs. Antiviral Res 2017, 143, 151–161. DOI: 10.1016/j.antiviral.2017.04.005.
   PubMed Web of Science ®Google Scholar
• Ehteshami, M.; Tao, S.; Ozturk, T.; Zhou, L.; Cho, J. H.; Zhang, H.; Amiralaei, S.; Shelton, J. R.; Lu, X.; Khalil, A.; et al. Biochemical Characterization of the Active anti-Hepatitis C Virus Metabolites of 2,6-Diaminopurine Ribonucleoside Prodrug Compared to Sofosbuvir and BMS-986094. Antimicrob. Agents Chemother. 2016, 60, 4659–4669. DOI: 10.1128/AAC.00318-16.
   PubMed Web of Science ®Google Scholar
• Zhou, L.; Zhang, H.; Tao, S.; Bassit, L.; Whitaker, T.; McBrayer, T. R.; Ehteshami, M.; Amiralaei, S.; Pradere, U.; Cho, J. H.; et al. β-D-2'-C-Methyl-2,6-Diaminopurine Ribonucleoside Phosphoramidates Are Potent and Selective Inhibitors of Hepatitis C Virus (HCV) and Are Bioconverted Intracellularly to Bioactive 2,6-Diaminopurine and Guanosine 5'-Triphosphate Forms. J. Med. Chem. 2015, 58, 3445–3458. DOI: 10.1021/jm501874e.
   PubMed Web of Science ®Google Scholar
• Anwar-Mohamed, A.; Barakat, K. H.; Bhat, R.; Noskov, S. Y.; Tyrrell, D. L.; Tuszynski, J. A.; Houghton, M. A Human Ether-á-Go-Go-Related (hERG) Ion Channel Atomistic Model Generated by Long Supercomputer Molecular Dynamics Simulations and Its Use in Predicting Drug Cardiotoxicity. Toxicol. Lett. 2014, 230, 382–392. DOI: 10.1016/j.toxlet.2014.08.007.
   PubMed Web of Science ®Google Scholar
• Li, W.; Trouba, K.; Ma, L.; Kwagh, J.; Storck, C.; Zhu, Y.; Flint, O.; Humphreys, W. G.; Wang, J.; Liu, A.; et al. In Vitro Metabolite Formation in Human Hepatocytes and Cardiomyocytes and Metabolism and Tissue Distribution in Monkeys of the 2'-C-Methylguanosine Prodrug BMS-986094. Int. J. Toxicol. 2017, 36, 35–49. DOI: 10.1177/1091581816683642.
   Web of Science ®Google Scholar
• S-(2-(((((2R,3R,4R,5R)-5-(2-Amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(benzylamino)phosphoryl)oxy)ethyl) 3-hydroxy-2,2-dimethylpropanethioate.
   Google Scholar
• Cretton-Scott, E.; Perigaud, C.; Peyrottes, S.; Licklider, L.; Camire, M.; Larsson, M.; La Colla, M.; Hildebrand, E.; Lallos, L.; Bilello, J.; et al. In Vitro Antiviral Activity and Pharmacology of IDX184, a Novel and Potent Inhibitor of HCV Replication. J. Hepatol. 2008, 48, S220. DOI: 10.1016/S0168-8278(08)60590-5.
   Web of Science ®Google Scholar
• Zhou, X. J.; Pietropaolo, K.; Chen, J.; Khan, S.; Sullivan-Bolyai, J.; Mayers, D. Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects. Antimicrob. Agents Chemother. 2011, 55, 76–81. DOI: 10.1128/AAC.01101-10.
   PubMed Web of Science ®Google Scholar
• Isopropyl 3-(2-(((((2R,3R,4R,5R)-5-(2,6-diamino-9H-purin-9-yl)-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(((S)-1-isopropoxy-1-oxopropan-2-yl)amino)phosphoryl)oxy)phenyl)propanoate.
   Google Scholar
• Hutchins, J.; Chanberlain, S.; Chang, C.; Ganguly, B.; Gorovits, E.; Hall, A.; Henson, G.; Kolykhalov, A.; Liu, Y.; Muhammad, J.; et al. In Vitro Activity and in Vivo Pharmacokinetics of Highly Potent Phosphoramidate Nucleoside Analogue Inhibitors of Hepatitis C NS5B. Antivir. Res 2009, 82, A28. DOI: 10.1016/j.antiviral.2009.02.047.
   Web of Science ®Google Scholar
• Sommadossi, J.-P. Gosselin, G.; Pierra, C.; Perigaud, C.; Peyrottes, S. Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections. WO2008082601 July 10, 2008.
   Google Scholar
• Fromentin, E.; Gavegnano, C.; Obikhod, A.; Schinazi, R. F. Simultaneous Quantification of Intracellular Natural and Antiretroviral Nucleosides and Nucleotides by Liquid Chromatography-Tandem Mass Spectrometry. Anal. Chem. 2010, 82, 1982–1989. DOI: 10.1021/ac902737j.
   PubMed Web of Science ®Google Scholar
• Zhang, H-w.; Zhou, L.; Coats, S. J.; McBrayer, T. R.; Tharnish, P. M.; Bondada, L.; Detorio, M.; Amichai, S. A.; Johns, M. D.; Whitaker, T.; Schinazi, R. F. Synthesis of Purine Modified 2’-C-Methyl Nucleosides as Potential anti-HCV Agents. Bioorg. Med. Chem. Lett. 2011, 21, 6788–6792. DOI: 10.1016/j.bmcl.2011.09.034.
   PubMedGoogle Scholar
• Zhou, L.; Zhang, H.; Tao, S.; Ehteshami, M.; Cho, J. H.; McBrayer, T. R.; Tharnish, P.; Whitaker, T.; Amblard, F.; Coats, S. J.; Schinazi, R. F. Synthesis and Evaluation of 2,6-Modified Purine 2′-C-Methyl Ribonucleosides as Inhibitors of HCV Replication. ACS Med. Chem. Lett. 2016, 7, 17–22. DOI: 10.1021/acsmedchemlett.5b00402.
   PubMed Web of Science ®Google Scholar
• McGuigan, C.; Perrone, P.; Madela, K.; Neyts, J. The Phosphoramidate ProTide Approach Greatly Enhances the Activity of β-2'-C-Methylguanosine against Hepatitis C Virus. Bioorg. Med. Chem. Lett. 2009, 19, 4316–4320. DOI: 10.1016/j.bmcl.2009.05.122.
   PubMed Web of Science ®Google Scholar
• Rondla, R.; Coats, S. J.; McBrayer, T. R.; Grier, J.; Johns, M.; Tharnish, P. M.; Whitaker, T.; Zhou, L.; Schinazi, R. F. Anti-Hepatitis C Virus Activity of Novel β-D-2′-C-Methyl-4′-Azido Pyrimidine Nucleoside Phosphoramidate Prodrugs. Antiviral Chem. Chemother. 2009, 20, 99–106. DOI: 10.3851/IMP1400.
   PubMedGoogle Scholar
• Stuyver, L. J.; Whitaker, T.; McBrayer, T. R.; Hernandez-Santiago, B. I.; Lostia, S.; Tharnish, P. M.; Ramesh, M.; Chu, C. K.; Jordan, R.; Shi, J.; et al. A Ribonucleoside Analogue That Blocks the Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture. Antimicrob. Agents Chemother 2003, 47, 244–254. DOI: 10.1128/AAC.47.1.244-254.2003.
   PubMed Web of Science ®Google Scholar
• Schinazi, R. F.; Sommadossi, J. P.; Saalmann, V.; Cannon, D. L.; Xie, M.; Hart, G. C.; Smith, G. A.; Hahn, E. F. Activities of 3′-Azido-3′-Deoxythymidine Nucleotide Dimers in Primary Lymphocytes Infected with Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother 1990, 34, 1061–1067. DOI: 10.1128/AAC.34.6.1061.
   PubMed Web of Science ®Google Scholar
• Stuyver, L. J.; Lostia, S.; Adams, M.; Mathew, J.; Pai, B. S.; Grier, J.; Tharnish, P.; Choi, Y.; Chong, Y.; Choo, H.; et al. Antiviral Activities and Cellular Toxicities of Modified 2′,3′-Dideoxy-2′,3′-Didehydrocytidine Analogues. Antimicrob. Agents Chemother 2002, 46, 3854–3860. DOI: 10.1128/AAC.46.12.3854-3860.2002.
   PubMed Web of Science ®Google Scholar
• Sofia, M. J.; Bao, D.; Chang, W.; Du, J. F.; Nagarathnam, D.; Rachakonda, S.; Reddy, P. G.; Ross, B. S.; Wang, P. Y.; Zhang, H. R.; et al. Discovery of a beta-D-2'-Deoxy-2'-Alpha-Fluoro-2'-beta-C-Methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus. J. Med. Chem. 2010, 53, 7202–7218. DOI: 10.1021/jm100863x.
   PubMed Web of Science ®Google Scholar
• Mandenius, C. F.; Steel, D.; Noor, F.; Meyer, T.; Heinzle, E.; Asp, J.; Arain, S.; Kraushaar, U.; Bremer, S.; Class, R.; et al. Cardiotoxicity Testing Using Pluripotent Stem Cell-Derived Human Cardiomyocytes and State-of-the-Art Bioanalytics: A Review. J. Appl. Toxicol. 2011, 31, 191–205. DOI: 10.1002/jat.1663.
   PubMed Web of Science ®Google Scholar
• Liu, Y. M.; Shim, E.; Nguyen, P.; Gibbons, A. T.; Mitchell, J. B.; Poirier, M. C. Tempol Protects Cardiomyocytes from Nucleoside Reverse Transcriptase Inhibitor-Induced Mitochondrial Toxicity. Toxicol. Sci 2014, 139, 133–141. DOI: 10.1093/toxsci/kfu034.
   PubMed Web of Science ®Google Scholar
• Lund, K. C.; Wallace, K. B. Direct Effects of Nucleoside Reverse Transcriptase Inhibitors on Rat Cardiac Mitochondrial Bioenergetics. Mitochondrion 2004, 4, 193–202. 4, DOI: 10.1016/j.mito.2004.06.009.
   PubMed Web of Science ®Google Scholar
• Lewis, W. Mitochondrial DNA Replication, Nucleoside Reverse-Transcriptase Inhibitors, and AIDS Cardiomyopathy. Prog. Cardiovasc. Dis. 2003, 45, 305–318. DOI: 10.1053/pcad.2003.3.
   PubMed Web of Science ®Google Scholar
• Tao, S.; Zhou, L.; Zhang, H.; Zhou, S.; Amiralaei, S.; Shelton, J.; Coats, S. J.; Schinazi, R. F. Comparison of Three 2'-C-Methyl Guanosine Prodrugs for Hepatitis C Including a Novel β-D-2'-C-Me-2,6-Diaminopurine Ribonucleoside Phosphoramidate (RS-1389): Interspecies Hepatocyte and Human Cardiomyocyte Metabolism Profiles (Poster). Hepatology 2014, 60, 1170a–1171a.
   PubMed Web of Science ®Google Scholar